Synergizing global clinical trials data: GLP-1 receptor agonist safety and novel clinical applicationsSynergizing global clinical trials data: GLP-1 receptor agonist safety and novel clinical applications
A research team led by the Department of Medicine, under the School of Clinical Medicine, LKS Faculty of Medicine of the University of Hong Kong (HKUMed), has synergized the impacts of worldwide clinical trial data through a series of meta-analyses on GLP‑1 receptor agonists, an emerging cardiometabolic drug, offering in-depth insights into its safety profile Read More
New tool spots early signs of infection after breast cancer reconstructionNew tool spots early signs of infection after breast cancer reconstruction
In the U.S., one in eight women will get breast cancer in their lifetime, and about half of them will have mastectomies. Many of those women opt to have their breasts surgically reconstructed, most commonly with implants, but a relatively high percentage develop infections after implant surgery, requiring intravenous antibiotics and often removal of the implant. This can lead to additional surgeries, delays in cancer care and increased costs, as well as added emotional distress for women already under strain from cancer diagnosis and treatment.
‘Sticky coat’ boosts triple negative breast cancer’s ability to metastasize’Sticky coat’ boosts triple negative breast cancer’s ability to metastasize
Researchers at Baylor College of Medicine have uncovered a strategy that triple negative breast cancer (TNBC) cells use to boost their ability to metastasize, or spread to other organs. Metastasis is the leading cause of cancer-related deaths and scientists are investigating ways to prevent it.
Use of GLP-1 Drugs Under Scrutiny at Winter OlympicsUse of GLP-1 Drugs Under Scrutiny at Winter Olympics
(MedPage Today) — As the Winter Olympic Games get underway, the World Anti-Doping Agency (WADA) is monitoring an unexpected class of drugs: GLP-1 receptor agonists. An advisory group that makes recommendations about WADA’s list of prohibited… (MedPage Today) — As the Winter Olympic Games get underway, the World Anti-Doping Agency (WADA) is monitoring an Read More
STAT+: Pharmalittle: We’re reading about TrumpRx, Hims & Hers selling compounded Wegovy pill, and moreSTAT+: Pharmalittle: We’re reading about TrumpRx, Hims & Hers selling compounded Wegovy pill, and more
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, so far, appears rather modest, given the frigid conditions awaiting us. We expect to catch up on our reading, check in on one Read More
STAT+: IPOs, GLP-1s, and challenges with a gene therapySTAT+: IPOs, GLP-1s, and challenges with a gene therapy
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve made it to the end of what’s felt like an extremely long week. Wishing you all a restful weekend and lots of Super Bowl dips. Roivant’s immune drug helped treat rare Read More
Why some breast cancers evade treatment: Protein secreted by T cells may explain resistant tumorsWhy some breast cancers evade treatment: Protein secreted by T cells may explain resistant tumors
Up to 20% of hormone receptor-positive breast cancers don’t respond to antiestrogen therapies. A study led by researchers at UT Southwestern, published in the Journal of Clinical Investigation, suggests that a protein secreted by immune cells within these tumors causes them to grow even in the absence of estrogen.
Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1sChallenges for a crucial sickle cell treatment and the latest outlook for GLP-1s
On this week’s episode of The Readout LOUD: two starkly different financial outlooks from Novo Nordisk and Eli Lilly, a psychedelics drug from Compass Pathways encountered a roadblock with the Trump White House, and a closer look at why manufacturing problems have slowed the rollout of a crucial sickle cell treatment. It’s our pre-Super Bowl show, Read More
STAT+: Novo Nordisk accuses Hims & Hers of ‘illegal mass compounding’ over a cheaper version of Wegovy pillSTAT+: Novo Nordisk accuses Hims & Hers of ‘illegal mass compounding’ over a cheaper version of Wegovy pill
In an unexpected move, Hims & Hers is making available a cheaper, compounded version of the Wegovy weight loss pill sold by Novo Nordisk, prompting the drugmaker to accuse the telehealth platform of “illegal mass compounding.” In announcing its move, Hims & Hers said it would make compounded copies of Wegovy available on its platform Read More
Hims & Hers Launches Copy of Wegovy Pill, Prompting Legal ThreatsHims & Hers Launches Copy of Wegovy Pill, Prompting Legal Threats
(MedPage Today) — Telehealth company Hims & Hers said Thursday it will launch a cheaper, off-brand version of the weight-loss pill semaglutide (Wegovy), just weeks after drugmaker Novo Nordisk launched its highly anticipated reformulation… (MedPage Today) — Telehealth company Hims & Hers said Thursday it will launch a cheaper, off-brand version of the weight-loss Read More